Pharma: Bayer erhält grünes Licht für Schlaganfall-Medikament
Für die Pharmasparte ist die US-Zulassung entscheidend: Ihr Bestseller Xarelto verliert an Umsatz. Asundexian soll die Lücke schließen – vor allem in den USA, wo Bayer am schnellsten wächst.
The U.S. drug regulator, the FDA, has granted Bayer's new stroke medication, Asundexian, approval, marking a significant growth driver for the pharmaceutical giant, as the company announced on Tuesday night in Leverkusen. The drug is designed to significantly reduce the risk of a second stroke and will be the first product in a new class of active substances available in the crucial U.S. market.
Bayer shares briefly surged two percent on the stock exchange on Tuesday, reaching a yearly high of 57.78 euros. Asundexian aims to replace sales lost to generics that have been taking market share from Bayer's current bestseller, Xarelto. "We are far from the end of our growth in the U.S. Asundexian is a key building block in this strategy," said US CEO Sebastian Guth, who also oversees pharmaceutical operations across all markets.
The U.S. is Bayer's largest and fastest-growing pharmaceutical market, accounting for 35 percent of the company's pharmaceutical revenue, up from around 20 percent when Guth arrived in the country in 2018.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Pharma: Bayer Receives US Approval for Important Stroke Medication handelsblatt.com
